2025-08-26 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the data provided, formatted as a concise English report.

**TG Therapeutics Inc. (TGTX) Analysis**

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO)**

*   **TGTX Total Return:** 48.32%
*   **VOO Total Return:** 38.23%
*   **Absolute Spread:** 14.2%
*   **Relative Spread (Percentile):** 15.5%

*Analysis:* TGTX has outperformed the S&P 500 by 14.2% in total return. However, a relative spread of 15.5% suggests that this outperformance is relatively low compared to its historical performance range.

**Alpha, Beta Analysis**

| Year       | CAGR     | MDD   | Alpha  | Beta  | Cap(B) |
|------------|----------|-------|--------|-------|--------|
| 2015-2017  | -6.0%    | 56.5% | -6.0%  | 1.0   | 1.3    |
| 2016-2018  | -8.0%    | 58.6% | -8.0%  | 1.0   | 0.7    |
| 2017-2019  | 74.0%    | 58.6% | 74.0%  | 1.0   | 1.8    |
| 2018-2020  | 402.0%   | 58.6% | 402.0% | 1.0   | 8.2    |
| 2019-2021  | 125.0%   | 63.5% | 124.0% | -0.1  | 3.0    |
| 2020-2022  | -76.0%   | 70.4% | -65.0% | 0.1   | 1.9    |
| 2021-2023  | -350.0%  | 70.4% | -360.0%| 0.0   | 2.7    |
| 2022-2024  | 71.0%    | 73.1% | 41.0%  | 0.1   | 4.8    |
| 2023-2025  | 55.0%    | 73.1% | 11.0%  | -0.0  | 4.5    |

*Analysis:* The table shows varying performance across different periods. Notice the significant volatility (high MDD) and fluctuating Alpha, indicating periods of both strong outperformance and underperformance. Beta hovers around 0 or 1.0, suggesting market sensitivity that doesn't show much of an indication.
CAGR shows significant changes every year, so it is necessary to check company news continuously.

**2. Recent Price Action**

*   **Current Price:** $28.53
*   **Previous Close:** $29.445
*   **Change:** -3.11%
*   **5-day Moving Average:** $28.595
*   **20-day Moving Average:** $29.4738
*   **60-day Moving Average:** $34.5835

*Analysis:* The stock price has declined by 3.11%. The current price is below both the 5-day and 20-day moving averages, suggesting short-term downward momentum. The price is significantly below the 60-day moving average, indicating potential longer-term weakness.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.3237 (Low Risk)
*   **RSI:** 50.90
*   **PPO:** 0.863
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (18 shares - Safe - MRI:0.32)
*   **Recent (20-day) Relative Spread Change:** +0.7 (Short-term Increase)
*   **Expected Return:** 31.2% (vs. S&P 500, Long-Term)

*Analysis:*
*   The low MRI suggests relatively stable market conditions for the stock.
*   RSI around 50 is neutral.
*   PPO is slightly positive but close to zero.
*   The Hybrid Signal recommends buying with 90% of available cash.
*   The positive change in the relative spread suggests recent positive momentum compared to the S&P 500.
*   The expected return is quite high, indicating significant potential for long-term outperformance.
*   The price change is relatively large, it should be noted continuously

**4. Recent News & Events**

*   **2025-08-25:** Major business developments, regulatory changes, or market events.
*   **2025-08-24:** Analyst discussion of recent performance and outlook.
*   **2025-08-26:** Notable stock volatility.
*   **2025-08-23:** Market experts highlighting risks and opportunities.

*Analysis:* Recent news indicates volatility and significant events affecting the stock. Investors should monitor news and company announcements closely.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-08-08 | 0.19 | 0.14 B$  |
| 2025-05-09 | 0.03 | 0.12 B$  |
| 2024-11-07 | 0.03 | 0.08 B$  |
| 2024-08-09 | 0.05 | 0.07 B$  |
| 2025-08-08 | 0.05 | 0.07 B$  |

*Analysis:*
*   The most recent EPS (0.19) is notably higher than previous quarters.
*   Revenue has generally been increasing, with the latest quarter showing the highest revenue (0.14B$).

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.14B  | 86.58%        |
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.28B  | 10.20%  |
| 2025-03-31 | $0.24B  | 2.13%   |
| 2024-12-31 | $0.22B  | 10.49%  |
| 2024-09-30 | $0.19B  | 2.02%   |
| 2024-06-30 | $0.18B  | 3.87%   |

*Analysis:*
*   Revenue has generally been increasing over the past five quarters.
*   Profit margins are consistently high, indicating efficient operations.
*   Equity has been growing, suggesting improved financial health.
*   ROE fluctuates, but the latest value is reasonably high.

**7. Overall Analysis & Conclusion**

TG Therapeutics Inc. shows a mixed picture. It has recently outperformed the S&P 500, but the magnitude of outperformance is not historically significant relative to the high volatility. Recent price action suggests a short-term downtrend. Technical indicators are neutral. Financial performance shows improving revenue and strong profitability, although ROE is not consistent.

**Key Considerations:**

*   **Recent Volatility:** The news and price action indicate recent volatility, potentially driven by company-specific events.
*   **High Expected Return:** The high expected return suggests the potential for significant future gains if the company's growth plans materialize.
*   **Earnings Improvement:** The recent improvement in EPS and revenue is a positive sign.
*   **Monitor News:** Closely monitor news and company announcements for updates on the company's developments.

**Recommendation:** Given the volatility and potential upside, a balanced approach is warranted. The Hybrid Signal recommends buying, but investors should proceed with caution, closely monitoring company news and market conditions. A long-term, incremental investment strategy might be suitable for those comfortable with the inherent risks in the biotechnology sector.
